Trial Profile
Study of the beneficial effect of Canagliflozin on nocturnal home BP in Japanese T2DM patients(SHIFT-J STUDY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SHIFT-J
- 23 Sep 2018 Results published in the Journal of Clinical Hypertension (Greenwich)
- 11 Jun 2018 Primary endpoint has not been met.
- 11 Jun 2018 Results presented at the 28th European Meeting on Hypertension and Cardiovascular Protection